Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

PCV21 · Capvaxive

Vaccine (Recombinant protein vaccine) · Immune activation, directed at Streptococcus pneumoniae capsular polysaccharides (serotypes 3, 6A, 7F, 8, 9N, 1 · developed by Merck Sharp & Dohme LLC

Approved FDA, Jun 2024
1 Registered trials

What is PCV21?

PCV21 (Capvaxive) is a 21-valent pneumococcal conjugate vaccine. Its polysaccharides from 21 Streptococcus pneumoniae serotypes are each conjugated to the CRM197 carrier protein, inducing active immunization against pneumococcal disease when given intramuscularly.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Capvaxive
Drug type
Vaccine (Recombinant protein vaccine)
Targets
Streptococcus pneumoniae capsular polysaccharides (serotypes 3, 6A, 7F, 8, 9N, 1 (antigen)
Mechanism
Immune activation, directed at Streptococcus pneumoniae capsular polysaccharides (serotypes 3, 6A, 7F, 8, 9N, 1
Therapy area
Infectious disease
Developer
Merck Sharp & Dohme LLC
In trials of
PCVX
FDA status
Approved as Capvaxive (June 17, 2024), BLA125814

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07284654 Phase 3 Pneumococcal Disease Completed PCVX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Pneumococcal Disease

Sources

Updated Oct 25, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.